Drug conjugated nanoparticles activated by cancer cell specific mRNA.

about

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.Nanoparticles-Emerging Potential for Managing Leukemia and Lymphoma.

P2860

Q30354652-55CF0A01-93E2-43B4-A1C6-4A4273B97E03 Q48540669-9E28227B-DF4B-4CFD-9C3A-05E426302044

P2860

Drug conjugated nanoparticles activated by cancer cell specific mRNA.

Item

http://www.wikidata.org/entity/Q42363695

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Drug conjugated nanoparticles activated by cancer cell specific mRNA.

@en

Drug conjugated nanoparticles activated by cancer cell specific mRNA.

@nl

type

Item

label

Drug conjugated nanoparticles activated by cancer cell specific mRNA.

@en

Drug conjugated nanoparticles activated by cancer cell specific mRNA.

@nl

prefLabel

Drug conjugated nanoparticles activated by cancer cell specific mRNA.

@en

Drug conjugated nanoparticles activated by cancer cell specific mRNA.

@nl

P1476

Drug conjugated nanoparticles activated by cancer cell specific mRNA.

@en

P2093

David J Gordon

http://www.w3.org/2001/XMLSchema#string

Edward A Zamora

http://www.w3.org/2001/XMLSchema#string

Jordan A Naumann

http://www.w3.org/2001/XMLSchema#string

Joseph A Piccirilli

http://www.w3.org/2001/XMLSchema#string

Nan-Sheng Li

http://www.w3.org/2001/XMLSchema#string

Nathan P Gossai

http://www.w3.org/2001/XMLSchema#string

Peter M Gordon

http://www.w3.org/2001/XMLSchema#string

P2860

Survivin - biology and potential as a therapeutic target in oncology

Alkyne-azide "click" chemistry in designing nanocarriers for applications in biology

Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia

The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia

Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma

The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.

Target profiling of small molecules by chemical proteomics.

Gold nanoparticles for biology and medicine.

Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.

Multiplexed nanoflares: mRNA detection in live cells.

P304

38243-38256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.9430

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27203672

http://www.w3.org/2001/XMLSchema#string

P932

5122386

http://www.w3.org/2001/XMLSchema#string

Drug conjugated nanoparticles activated by cancer cell specific mRNA.

about

P2860

P2860

Drug conjugated nanoparticles activated by cancer cell specific mRNA.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932